In a landmark advancement, the National Health Service (NHS) will soon provide a pioneering treatment capable of delaying the onset of type 1 diabetes by up to three years. The National Institute for Health and Care Excellence (NICE) has officially approved teplizumab, a drug hailed by Diabetes UK as ushering in a new era of type 1 diabetes management.
Teplizumab, marketed as Tzield by Sanofi, is designed for children aged eight and older, as well as adults recently diagnosed with early-stage type 1 diabetes before symptoms emerge. Currently, around 400,000 people in the UK live with type 1 diabetes, an autoimmune disease where the body attacks the insulin-producing cells of the pancreas.
Administered as a one-time 14-day intravenous drip, teplizumab ‘re-educates’ the immune system to prevent this attack, effectively postponing the progression of the disease. This delay allows individuals more time to live freely without the immediate need for insulin management, granting especially children a crucial window of normalcy and less medical burden.
READ MORE: Cheltenham’s First Neighbourhood Development Plan Approved After a Decade of Effort
READ MORE: Gloucestershire Steam Railway Suspends Services Amid Extreme Heat Warning
NICE estimates approximately 1,100 patients could receive teplizumab in its first year of availability, with about 820 eligible annually thereafter. Diabetes UK’s research director, Dr Elizabeth Robertson, highlighted the significance: “This is the first treatment in over a century that targets type 1 diabetes at its root cause, marking a monumental step beyond simply managing symptoms.”
Early diagnosis is essential to maximize teplizumab’s benefits. To enhance detection, two UK screening programs are underway: the Early Surveillance for Autoimmune Diabetes (Elsa) study, focusing on children aged 2 to 17, and the T1DRA study for adults 18 to 70. Identifying at-risk individuals early opens the door to timely intervention with teplizumab.
Helen Knight, NICE’s director of medicines evaluation, emphasized the rigorous assessment behind the decision: “Our recommendation ensures patients get access to a treatment that can significantly delay symptomatic diabetes, balancing clinical benefit with responsible use of NHS resources.”
Personal stories underscore the hope offered. Elena Boichak from Newbury enrolled her son Dima in the Elsa screening. Diagnosed at stage 2 type 1 diabetes, Dima has gained invaluable ‘time’ free from insulin dependency. “Every month teplizumab buys Dima as a child is precious,” said Elena. “This treatment changes how families face this diagnosis—from feeling overwhelmed to feeling prepared.”
Karen Addington, chief executive of Breakthrough T1D, expressed optimism for the community: “Teplizumab gives families more years without the relentless demands of managing type 1 diabetes, truly an incredible breakthrough.”
Teplizumab’s regimen involves daily infusions lasting about 30 minutes over two weeks, starting at a low dose that is gradually increased. The one-off treatment has the potential to reshape the future of type 1 diabetes care in the UK, offering hope where there was little before.